Unresectable Extrahepatic Bile Duct Cancer Completed Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0028791 (Unresectable Extrahepatic Bile Duct Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00085410Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTreatment